Side Effect Kills Cancer Patient In Stemline Therapeutics Drug Trial

Feb 2, 2017, 08:59 by Michael Croft

TheStreet | Stemline's SL-401 has demonstrated robust overall tumor response rates in its clinical trial but the drug is also now tied to three patient deaths from capillary leak syndrome.

February 02, 2017 | Stemline's SL-401 has demonstrated robust overall tumor response rates in its clinical trial but the drug is also now tied to three patient deaths from capillary leak syndrome. TheStreet